| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4257 | Protac D9a-2 | Novel SLC-targeting chimeric degrader, targeting SLC9A1 and other SLC9 family members, effectively impairing pH homeostasis and differentially killing cancer cell lines |
|
| DCC4258 | Protac Degrader Pp-c8 | Novel noncovalent CDK12/13 dual inhibitor, inducing potent and selective CDK12-CycK degradation without affecting CDK13, suppressing DDR-associated genes and induced synthetic lethality with Olaparib |
|
| DCC4259 | Protac Hl-8 | Novel PI3K degrader, showing a significant and complete degradation effect on PI3K kinase at a concentration of 10 μM within 8 h |
|
| DCC4260 | Protac Nr-7h | Novel potent and selective p38α and p38β degrader |
|
| DCC4261 | Protac P22a | Novel degrader of HMGCR protein, potently blocking cholesterol biosynthesis with less compensatory upregulation of HMGCR |
|
| DCC4262 | Protac P3 | Novel potent epidermal growth factor receptor (EGFR) degrader, inducing EGFRdel19 and EGFRL858R/T790M degradation with DC50 values of 0.51 and 126 nM, showing potent anti-proliferative activity against HCC827 and H1975 cell lines with IC50 values of 0.83 |
|
| DCC4263 | Protac(h-pgds)-1 | Novel potent degrader of H-PGDS protein via the ubiquitin-proteasome system and in the suppression of prostaglandin D2 (PGD2) production |
|
| DCC4264 | Protac_erralpha | Proteolysis targeting chimeras (PROTAC), providing broad tissue distribution and knockdown of the targeted ERRalpha protein in tumor xenografts |
|
| DCC4265 | Protac_ripk2 | Proteolysis targeting chimeras (PROTAC), providing broad tissue distribution and knockdown of the targeted RIPK2 protein in tumor xenografts |
|
| DCC4266 | Protac-12 | Novel SirReal-based PROTAC, inducing isotype-selective Sirt2 degradation, resulting in the hyperacetylation of the microtubule network coupled with enhanced process elongation |
|
| DCC4267 | Protac-3 (fak) | Novel selective and potent Fak degrader |
|
| DCC4268 | Protac-6c | The most potent and selective ERRα degrader |
|
| DCC4269 | Protac-i | Novel PROTAC, targeting steroid hormone receptors for ubiquitination and degradation |
|
| DCC4270 | Protegenin A | Novel bacterial polyyne contributing to the antioomycete and plant-protective effects of P. protegens |
|
| DCC4271 | Prs-211375 | Novel selective CB2 agonist (CB2: 17.4 nM and CB1: 5585 nM) |
|
| DCC4272 | Pr-snf | Novel potent and selective inhibitor of SETD2 |
|
| DCC4273 | Prucalopride Hydrochloride | Selective 5-HT4 agonist |
|
| DCC4274 | Prx-07034 | Novel selective 5-HT6 receptor antagonist, enhancing cognition and memory and potently decreasing food intake and body weight in rodents |
|
| DCC4275 | Prx-08066 Maleate Featured | Novel potent and selective 5-HT2B receptor antagonist |
|
| DCC4276 | Ps1145 Dihydrochloride | Novel inhibitor of upstream IκB kinase (IKK), specifically inhibiting the IκB phosphorylation and degradation and the subsequent nuclear translocation of NF-κB |
|
| DCC4277 | Ps121912 | Highly potent and selective VDR-coactivator inhibitor |
|
| DCC4278 | Psammaplysene B | Naturally occurring inhibitor of FOXO1a nuclear export |
|
| DCC4279 | Psammaplysin F | Unique inhibitor of bacterial chromosomal partitioning, increasing the efficacy of bortezomib and sorafenib through regulation of stress granule formation |
|
| DCC4280 | Psb-1011 | Potent competitive antagonist and positive modulator of the P2X2 receptor with >100-fold selectivity versus P2X4, P2X7, and several investigated P2Y receptor subtypes (P2Y(2,4,6,12)) |
|
| DCC4281 | Psb-10129 | Positive modulator of ATP effects at P2X2 receptors |
|
| DCC4282 | Psb-10211 | Potent competitive antagonist and positive modulator of the P2X2 receptor |
|
| DCC4283 | Psb-12105 | Novel fluorescent-labeled selective adenosine A2B receptor antagonist |
|
| DCC4284 | Psb-1410 | Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B) |
|
| DCC4285 | Psb-1434 Featured | Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B) |
|
| DCC4286 | Psb-1491 Featured | Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B) |
|
